Article
In vitro metabolism of canagliflozin in human liver, kidney, intestine microsomes, and recombinant uridine diphosphate glucuronosyltransferases (UGT) and the effect of genetic variability of UGT enzymes on the pharmacokinetics of canagliflozin in humans.
Journal of clinical pharmacology - 1 Sept 2015
Francke Stephan, Mamidi Rao N V S, Solanki Bhavna, Scheers Ellen, Jadwin Andrew, Favis Reyna, Devineni Damayanthi
Abstract excerpt
O-glucuronidation is the major metabolic elimination pathway for canagliflozin. The objective was to identify enzymes and tissues involved in the formation of 2 major glucuronidated metabolites (M7 and M5) of canagliflozin and subsequently to assess the impact of genetic variations in these uridine diphosphate glucuronosyltransferases (UGTs) on in vivo pharmacokinetics in humans. In vitro incubations with...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.